Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy

Gaia Spinetti; Elisa Avolio; Paolo Madeddu

doi:10.2217/rme-2020-0189

Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy

Gaia Spinetti, Elisa Avolio, Paolo Madeddu

Research output: Contribution to journal › Review article (Academic Journal) › peer-review

2 Citations (Scopus)

59 Downloads (Pure)

Abstract

In many countries, COVID-19 now accounts for more deaths per year than car accidents and even the deadliest wars. Combating the viral pandemics requires a coordinated effort to develop therapeutic protocols adaptable to the disease severity. In this review article, we summarize a graded approach aiming to shield cells from SARS-CoV-2 entry and infection, inhibit excess inflammation and evasion of the immune response, and ultimately prevent systemic organ failure. Moreover, we focus on mesenchymal stem cell therapy, which has shown safety and efficacy as a treatment of inflammatory and immune diseases. The cell therapy approach is now repurposed in patients with severe COVID-19. Numerous trials of mesenchymal stem cell therapy are ongoing, especially in China and the USA. Leader companies in cell therapy have also started controlled trials utilizing their quality assessed cell products. Results are too premature to reach definitive conclusions.

Original language	English
Pages (from-to)	477-494
Number of pages	18
Journal	Regenerative Medicine
Volume	16
Issue number	5
Early online date	14 May 2021
DOIs	https://doi.org/10.2217/rme-2020-0189
Publication status	Published - May 2021

Bibliographical note

Funding Information:
No writing assistance was utilized in the production of this manuscript. This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 ?Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19?. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Funding Information:
This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 ‘Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19’. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.

Research Groups and Themes

Covid19

Keywords

acute respiratory distress syndrome
coronavirus
cytokine storm
epithelial cells
infection
mesenchymal stem cells
vascular cells

Access to Document

10.2217/rme-2020-0189

Full-text PDF (author’s accepted manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Future Medicine at https://www.futuremedicine.com/doi/10.2217/rme-2020-0189?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed . Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 610 KB

Handle.net

Persistent link

2 Citations
1 Article (Academic Journal)

Murine studies and expressional analyses of human cardiac pericytes reveal novel trajectories of SARS-CoV-2 Spike protein-induced microvascular damage
Avolio, E., Srivastava, P., Jiahui, J., Carrabba, M., Tsang, C. T. W., Gu, Y., Thomas, A. C., Gupta, K., Berger, I., Emanueli, C. & Madeddu, P. R., 2 Jun 2023, In: Signal Transduction and Targeted Therapy. 8, 1, 232.
Research output: Contribution to journal › Article (Academic Journal) › peer-review

Open Access
File

1 Citation (Scopus)

43 Downloads (Pure)

Cite this

@article{fe2b3f90085c4c8e8161d667cae283e8,

title = "Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy",

abstract = "In many countries, COVID-19 now accounts for more deaths per year than car accidents and even the deadliest wars. Combating the viral pandemics requires a coordinated effort to develop therapeutic protocols adaptable to the disease severity. In this review article, we summarize a graded approach aiming to shield cells from SARS-CoV-2 entry and infection, inhibit excess inflammation and evasion of the immune response, and ultimately prevent systemic organ failure. Moreover, we focus on mesenchymal stem cell therapy, which has shown safety and efficacy as a treatment of inflammatory and immune diseases. The cell therapy approach is now repurposed in patients with severe COVID-19. Numerous trials of mesenchymal stem cell therapy are ongoing, especially in China and the USA. Leader companies in cell therapy have also started controlled trials utilizing their quality assessed cell products. Results are too premature to reach definitive conclusions.",

keywords = "acute respiratory distress syndrome, coronavirus, cytokine storm, epithelial cells, infection, mesenchymal stem cells, vascular cells",

author = "Gaia Spinetti and Elisa Avolio and Paolo Madeddu",

note = "Funding Information: No writing assistance was utilized in the production of this manuscript. This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 ?Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19?. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 {\textquoteleft}Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19{\textquoteright}. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.. All rights reserved.",

year = "2021",

month = may,

doi = "10.2217/rme-2020-0189",

language = "English",

volume = "16",

pages = "477--494",

journal = "Regenerative Medicine",

issn = "1746-0751",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Treatment of COVID-19 by stage

T2 - any space left for mesenchymal stem cell therapy

AU - Spinetti, Gaia

AU - Avolio, Elisa

AU - Madeddu, Paolo

N1 - Funding Information: No writing assistance was utilized in the production of this manuscript. This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 ?Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19?. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 ‘Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19’. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2021 Future Medicine Ltd.. All rights reserved.

PY - 2021/5

Y1 - 2021/5

N2 - In many countries, COVID-19 now accounts for more deaths per year than car accidents and even the deadliest wars. Combating the viral pandemics requires a coordinated effort to develop therapeutic protocols adaptable to the disease severity. In this review article, we summarize a graded approach aiming to shield cells from SARS-CoV-2 entry and infection, inhibit excess inflammation and evasion of the immune response, and ultimately prevent systemic organ failure. Moreover, we focus on mesenchymal stem cell therapy, which has shown safety and efficacy as a treatment of inflammatory and immune diseases. The cell therapy approach is now repurposed in patients with severe COVID-19. Numerous trials of mesenchymal stem cell therapy are ongoing, especially in China and the USA. Leader companies in cell therapy have also started controlled trials utilizing their quality assessed cell products. Results are too premature to reach definitive conclusions.

AB - In many countries, COVID-19 now accounts for more deaths per year than car accidents and even the deadliest wars. Combating the viral pandemics requires a coordinated effort to develop therapeutic protocols adaptable to the disease severity. In this review article, we summarize a graded approach aiming to shield cells from SARS-CoV-2 entry and infection, inhibit excess inflammation and evasion of the immune response, and ultimately prevent systemic organ failure. Moreover, we focus on mesenchymal stem cell therapy, which has shown safety and efficacy as a treatment of inflammatory and immune diseases. The cell therapy approach is now repurposed in patients with severe COVID-19. Numerous trials of mesenchymal stem cell therapy are ongoing, especially in China and the USA. Leader companies in cell therapy have also started controlled trials utilizing their quality assessed cell products. Results are too premature to reach definitive conclusions.

KW - acute respiratory distress syndrome

KW - coronavirus

KW - cytokine storm

KW - epithelial cells

KW - infection

KW - mesenchymal stem cells

KW - vascular cells

U2 - 10.2217/rme-2020-0189

DO - 10.2217/rme-2020-0189

M3 - Review article (Academic Journal)

C2 - 33988482

SN - 1746-0751

VL - 16

SP - 477

EP - 494

JO - Regenerative Medicine

JF - Regenerative Medicine

IS - 5

ER -

Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy

Abstract

Bibliographical note

Research Groups and Themes

Keywords

Access to Document

Handle.net

Fingerprint

Research output

Murine studies and expressional analyses of human cardiac pericytes reveal novel trajectories of SARS-CoV-2 Spike protein-induced microvascular damage

Cite this